IN BRIEF: Malin's Poseida Therapeutics signs agreement with Roche

Fri, 05th Aug 2022 19:38

Malin Corp PLC - Dublin-based investor in life sciences companies - Notes announcement from Nasdaq-listed Poseida Therapeutics Inc of its entry into a strategic collaboration and licence agreement with Roche Holding AG, for the development of allogeneic CAR-T therapies directed towards hematologic malignancies.

Poseida will receive USD110 million upfront, and can fain an additional USD110 million in near-term milestones and other payments.

Current stock price: EUR4.15

12-month change: down 38%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Related Shares

More News

1 May 2024 18:14

IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma

Malin Corp PLC - Dublin-based investor in life sciences companies - Investee company Poseida Therapeutics Inc enters into a research collaboration and...

21 Mar 2024 14:59

UK shareholder meetings calendar - next 7 days

28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

26 Jan 2024 14:30

TRADING UPDATES: Puma and Puma Alpha invest in Not Another Beer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

27 Oct 2023 15:17

IN BRIEF: Malin confirms new executive director joins board

Malin Corp PLC - Dublin-based investor in life sciences companies - Confirms that Fiona Dunlevy joins the board as an executive director. Outgoing Chi...